Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
October 09 2023 - 4:17PM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced that it will present interim monotherapy data from its
Phase 1/2 clinical trial evaluating HPN328 in small cell lung
cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster
presentation at the European Society of Medical Oncology Congress
(ESMO) 2023 taking place in Madrid, Spain from October 20-24,
2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from
Harpoon’s proprietary Tri-specific T cell Activating Construct
(TriTAC®) platform designed to recruit a patient’s own immune cells
to kill tumor cells.
“We are excited to present data from over 70 patients with
multiple tumor types in HPN328 monotherapy cohorts, with an
emphasis on our ongoing 1 mg priming cohorts with target doses up
to 24 mg. Full enrollment of these 1 mg priming dose cohorts will
be the basis for selecting our recommended Phase 2 dose(s) by the
end of this year. In our poster, we will share tolerability data
from all enrolled patients and preliminary response data in
patients at doses above the efficacy threshold of 1.215 mg,” said
Luke Walker, M.D., Chief Medical Officer for Harpoon
Therapeutics. “In addition to nearing completion of monotherapy
dose optimization, we have recently initiated enrollment in our
combination cohorts evaluating HPN328 plus atezolizumab to enable
future development in early lines of therapy.”
Details of the ESMO poster presentation are as follows:
Abstract Title: Interim Results from a Phase
1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended
DLL3-targeting T-Cell Engager in Patients (pts) with Small Cell
Lung Cancer (SCLC) and other Neuroendocrine Neoplasms
(NEN)Presentation Number: 698PSession
Number/Title: Developmental TherapeuticsSession
Date, Time: Monday, October 23, 2023, 12:00 – 13:00
CESTPresenter: Noura Choudhury,
M.D.Location: Hall 8
The poster will also be available on Harpoon’s website following
the presentation.
For more details about the ESMO Annual Meeting, please visit:
https://www.esmo.org/meeting-calendar/esmo-congress-2023
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel
TriTACs initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon has also developed a proprietary
ProTriTAC™ platform, which applies a prodrug concept to its
TriTAC platform to create a therapeutic T cell engager that
remains inactive until it reaches the tumor. Harpoon’s third
proprietary technology platform, extended release TriTAC-XR, is
designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“expect,” “will,” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include, but are not limited to, statements
about the expected timing, progress, and results of Harpoon
Therapeutics’ clinical trials, including interim results of
clinical trials and the safety and tolerability profile of product
candidates, the association of interim clinical data and
preclinical results with potential treatment outcomes and other
statements that are not historical fact. Many factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data observed during
clinical studies, preliminary data and trends may not be predictive
of future data or results, may not demonstrate safety or
efficacy or lead to regulatory approval by the FDA or other
regulatory agencies, clinical trial site activation or enrollment
rates that are lower than expected, changes in expected or existing
competition, changes in the regulatory environment, the
uncertainties and timing of the regulatory approval process, the
timing and results of unexpected litigation or other disputes, and
the sufficiency of Harpoon Therapeutics’ cash resources. These and
other factors that may cause Harpoon Therapeutics’ actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Harpoon
Therapeutics’ filings with the U.S. Securities and Exchange
Commission, including under “Risk Factors” in Harpoon Therapeutics’
quarterly report on Form 10-Q for the quarter ended June 30,
2023, and future filings by Harpoon Therapeutics. Except
as required by law, Harpoon Therapeutics assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Contacts:
Harpoon TherapeuticsAna Kaporakapor@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024